¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"site specific mutation"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
cold-sensitive mutation
Àú¿Â¹Î°¨µ¹¿¬º¯ÀÌ, Àú¿Â°¨¼ö¼ºµ¹¿¬º¯ÀÌ
conditional lethal mutation
Á¶°ÇÄ¡»çµ¹¿¬º¯ÀÌ
conditional mutation
Á¶°Çµ¹¿¬º¯ÀÌ
chromosomal mutation
¿°»öüµ¹¿¬º¯ÀÌ
chromosome mutation
¿°»öüµ¹¿¬º¯ÀÌ
drift mutation
¿¬¼Óº¯ÀÌ
dominant mutation
¿ì¼ºµ¹¿¬º¯ÀÌ
extragenic suppressor mutation
À¯ÀüÀڿܹßÇö¾ïÁ¦µ¹¿¬º¯ÀÌ
forward mutation
¾ÕÂʵ¹¿¬º¯ÀÌ, ÀüÇâµ¹¿¬º¯ÀÌ
frameshift mutation
ƲÀ̵¿µ¹¿¬º¯ÀÌ
genetic mutation
À¯Àüµ¹¿¬º¯ÀÌ
genomic mutation
À¯Àüüµ¹¿¬º¯ÀÌ
induced mutation
À¯¹ßµ¹¿¬º¯ÀÌ
loss-of-function mutation
±â´É¼Ò½Çµ¹¿¬º¯ÀÌ
missense mutation
°ú¿Àµ¹¿¬º¯ÀÌ, ¹Ì½º¼¾½ºµ¹¿¬º¯ÀÌ
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
site
ºÎÀ§
telomeric site
¸»´ÜºÎÀ§
web site
À¥½ÎÀÌÆ®
back mutation
¿ªµ¹¿¬º¯ÀÌ, º¹±Íµ¹¿¬º¯ÀÌ
chromosomal mutation
¿°»öüº¯ÀÌ, ¿°»öüµ¹¿¬º¯ÀÌ
cold-sensitive mutation
Àú¿Â¹Î°¨µ¹¿¬º¯ÀÌ
conditional mutation
Á¶°Çµ¹¿¬º¯ÀÌ
conditional lethal mutation
Á¶°ÇÄ¡»çµ¹¿¬º¯ÀÌ
dominant mutation
¿ì¼ºµ¹¿¬º¯ÀÌ
drift mutation
¿¬¼Óº¯ÀÌ
mutation detection
µ¹¿¬º¯À̰ËÃâ
extragenic suppressor mutation
À¯ÀüÀڿܹßÇö¾ïÁ¦µ¹¿¬º¯ÀÌ
forward mutation
ÀüÇâµ¹¿¬º¯ÀÌ
frequency mutation
µ¹¿¬º¯À̺óµµ
genetic mutation
À¯Àüµ¹¿¬º¯ÀÌ
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
plaque morphology mutation
ÇöóÅ© ÇüÅ µ¹¿¬º¯ÀÌ
plaque-type mutation
ÇöóÅ©Çü µ¹¿¬º¯ÀÌ
point mutation
Á¡ µ¹¿¬º¯ÀÌ
point mutation
Á¡µ¹¿¬º¯ÀÌ
population mutation
Áý´Ü±ºµ¹¿¬º¯ÀÌ(¡ÔÍæÔܨì¶).
privileged site
Ưº°°Ý¸®ºÎÀ§
receptor site
¼ö¿ëüºÎÀ§.
recessive mutation
¿¼ºµ¹¿¬º¯ÀÌ(æëàõÔÍæÔܨì¶).
recessive mutation
¿¼ºµ¹¿¬º¯ÀÌ
SDA= specific dynamic action
ƯÀ̵¿Àû ÀÛ¿ë.
age specific death rate
¿¬·Éº° »ç¸Á·ü
antigen, species-specific
Á¾Æ¯ÀÌÇ׿ø
antigen, tumor-specific
Á¾¾çƯÀÌÇ׿ø
antigen, tumor-specific transplantation
Á¾¾çƯÀÌ À̽ÄÇ׿ø
antigen,tumor-specific transplantation
Á¾¾ç ƯÀÌÀ̽Ä(ðþåË ÷åì¶ì¹ãÕ)
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
donor site
±Þ¿©ºÎ.
fundic site
ÀڱùٴÚÀÓ½Å
internal ribosomal entry site (IRES)
³»ºÎ ¸®º¸¼Ø °áÇÕºÎÀ§
mutational site
(µ¹¿¬)º¯ÀÌÁ¡.
packaging site
²Ù¸®±âºÎÀ§
placental site trophoblastic tumor
ŹݺÎÂøºÎÀ§ À¶¸ð»óÇǼºÁ¾¾ç
privileged site
Ưº°°Ý¸®ºÎÀ§
receptor site
¼ö¿ëüºÎÀ§.
variations of site
À§Ä¡º¯ÀÌ
web site
À¥ ½ÎÀÌÆ®
back mutation
¿ªº¯ÀÌ
chromosomal mutation
¿°»öü(µ¹¿¬)º¯ÀÌ.
cold-sensitive mutation
ÇÑ·©°¨¼ö¼º µ¹¿¬º¯ÀÌ
complementation of virus mutation
¹ÙÀÌ·¯½ºº¯ÀÌ (Áõ½Ä)º¸¿Ï(¡ñòãÖÜÍèÇ).
conditional lethal mutation
Á¶°ÇÄ¡»ç µ¹¿¬º¯ÀÌ
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½